David said gross margin was 82.1% for 2025 and 81% in the fourth quarter. He attributed the year’s results to inventory reserves booked during the year that he said would not recur, as well as a continuing product-mix impact tied to revenue-sharing arrangements for newer products.Cary said the company grew about 11% in 2025 despite disruptions, and expects 12% to 19% growth in 2026. Finance leader David added that Avita has historically grown at a compound annual growth rate of about 32% , and said manageme ...

R&D Meeting Overview - The R&D meeting of Sumitomo Pharma Company Limited is being conducted to discuss R&D progress, basic policy, and two major oncology products [1] - The meeting is scheduled to conclude at 15:40 [1] Attendees - Key attendees include Mr. Kimura (Representative Director, President and CEO), Mr. Sakai (Representative Director, Executive Vice President), Ms. Sato (Managing Executive Officer), and Mr. Murata (Global Strategy Oncology Lead) [2] - Mr. Kimura is expected to provide introductory remarks [2]

CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th. Management will host a conference call at 5:00 p.m. Eastern Time on February 26th ...

Core Viewpoint - Celularity Inc. has successfully sold approximately $126.3 million of unused New Jersey net operating losses (NOLs) and $1.9 million of unused New Jersey research and development (R&D) tax credits, resulting in net cash proceeds of $12.2 million, which will enhance the company's liquidity and support its regenerative medicine programs focused on longevity [1][2][3] Group 1: Financial Impact - The sale of NOLs and R&D tax credits generated $12.2 million in net cash proceeds for Celularity [1] - The total value of the unused NOLs sold was approximately $126.3 million, along with $1.9 million in R&D tax credits [1][2] Group 2: Program Details - The transaction was facilitated through New Jersey's Technology Business Tax Certificate Transfer Program, which allows qualified technology and life science companies to sell their NOLs and R&D tax credits for cash [2] - The program is managed by the New Jersey Economic Development Authority (NJEDA), aimed at promoting economic growth in the state [2] Group 3: Company Strategy - The funds received will provide non-dilutive, tax-free capital that strengthens Celularity's balance sheet and enhances liquidity [3] - The capital will support disciplined allocation towards commercial opportunities in GMP-level stem cell therapies and other regenerative medicine programs targeting longevity and human performance [3] Group 4: Company Overview - Celularity Inc. is focused on developing, manufacturing, and commercializing advanced biomaterial products and cell therapies derived from postpartum placenta [4] - The company aims to address significant unmet global needs for effective and affordable therapies targeting aging mechanisms such as cellular senescence and tissue degeneration [4]

SBC Medical Group Holdings Conference Summary Company Overview - SBC Medical Group Holdings is the largest aesthetic medical group in Japan, providing comprehensive management support services to franchise clinics and generating income through franchise fees [2][3] - The company has expanded its franchise clinics to 258 locations, serving approximately 6.5 million customers annually [3] Industry Insights - The aesthetic medicine market in Japan remains competitive but is showing signs of improvement compared to the previous year [22] - The average revenue per customer visit had temporarily declined but is now recovering due to strategic initiatives [4][22] Financial Performance - Sales declined in Q2 2025 due to business restructuring and franchise fee revisions, but signs of recovery are evident [4] - The company maintains a robust financial foundation with sufficient cash and deposits, and aims to sustain a high EBITDA margin [4][5] Global Expansion Strategy - SBC is focused on expanding its operations outside Japan, particularly in the U.S. and Southeast Asia, while also deepening its presence in the Japanese market [6][23] - The partnership with OrangeTwist, a U.S.-based med spa, is a key component of this strategy, allowing SBC to leverage OrangeTwist's platform and customer experience [9][10] Partnership with OrangeTwist - OrangeTwist operates 24 clinics across several U.S. states and is co-founded by industry veterans, providing a strong platform for collaboration [9][10] - The partnership aims to introduce differentiated experiences in both the U.S. and Japan, potentially including product distribution and joint clinics [12][14] M&A Strategy - SBC plans to pursue M&A opportunities primarily in Japan, leveraging its scale and operational efficiencies [19][21] - The company is also exploring potential acquisitions in Southeast Asia and the U.S. as part of its global strategy [20][21] Market Dynamics - The aesthetic market in the U.S. is experiencing consolidation, presenting opportunities for SBC to enter and grow [11] - SBC's flexible platform allows for adjustments in clinic offerings to meet diverse customer needs, including potential expansion into general medical areas like dentistry and orthopedics [24] Customer Experience and Treatment Differences - SBC emphasizes the importance of customer experience, noting that treatments popular in Japan may not translate directly to the U.S. market [32][33] - The company aims to learn from OrangeTwist's customer engagement strategies to enhance its offerings in the U.S. [34] Future Outlook - SBC's long-term goal is to become the preferred medical group globally by 2050, with a cautious and disciplined approach to expansion [13][18] - The company plans to gradually increase investments as it gains market knowledge and identifies successful strategies [17][18] Conclusion - SBC Medical Group Holdings is strategically positioned for growth through its strong domestic presence, international partnerships, and a focus on customer experience in the evolving aesthetic medicine market [35]

Core Insights - GelrinC-treated patients showed layered cartilage architecture similar to native hyaline cartilage, indicating true biological cartilage regeneration rather than just defect filling [1] - GelrinC limits fibrotic tissue overgrowth, which supports smoother joint motion and preserves natural biomechanics [1] Company Overview - Regentis Biomaterials Ltd. is a regenerative medicine company focused on innovative tissue repair solutions [1] - The company announced new long-term imaging data from a completed European clinical trial of GelrinC® [1] Clinical Trial Results - The clinical trial demonstrated that regenerated cartilage exhibits internal structural organization closely resembling healthy, native hyaline cartilage [1]

Core Insights - Bone Biologics Corporation achieved significant milestones in 2025, including the extension of rhNELL-1 shelf life, advancement of NB1 development, and a strengthened balance sheet while maintaining compliance with Nasdaq [1][2][5] 2025 Highlights - The company focused on strategic priorities across development, operations, and corporate governance to support ongoing programs and maintain organizational stability [3] - Key accomplishments included extending the validated shelf life of rhNELL-1 to 24 months, completing a public offering for gross proceeds of $5 million, and filing a U.S. patent application related to bone regeneration technology [5] - The company regained compliance with Nasdaq's minimum bid price requirement in June 2025, enhancing access to public capital markets [5] - Management increased investor engagement through participation in conferences and communication of progress in clinical and operational initiatives [5] Outlook for 2026 - The company plans to continue advancing its clinical-stage program and strengthening its operational foundation in 2026 [4] - Focus areas include the ongoing development of NB1, regulatory readiness, and commercialization planning [5] - The company aims to maintain prudent capital management while supporting scientific progress and shareholder engagement [5]

Core Insights - EUDA Health Holdings Limited is accelerating its longevity and regenerative medicine strategy by launching a comprehensive stem cell therapy platform and establishing its first clinic in Shenzhen, China [1][4] Group 1: Strategic Developments - The company has acquired distribution rights for T-cell immunotherapies from Shenzhen Inno Immune Co. Ltd., which specializes in autologous cellular therapeutics [2] - EUDA intends to acquire GO POSB Organoids Pte Ltd., a biotechnology company based in Singapore [2] Group 2: Facility and Technology Enhancements - EUDA is upgrading Shenzhen Inno's cGMP facility to create a state-of-the-art production and innovation center for stem cell treatments, incorporating GO POSB's iPSC technology and advanced stem cell technologies from Japanese partners [3] - The upgraded facility will support iPSC expansion, stem cell preparation, immune cell therapies, and the development of new treatments focused on immune health, skin health, and healthy aging [3] Group 3: Clinic Establishment and Services - A new longevity clinic has been established in Shenzhen in partnership with KB International Ltd., which will introduce Japanese longevity healthcare technologies [4] - The clinic will offer services aimed at enhancing longevity, slowing biological aging, strengthening immunity, and providing long-term health planning [4] Group 4: Company Vision and Market Position - The company aims to become a market leader in non-invasive and preventive healthcare, focusing on the fast-growing longevity sector to address the healthcare needs of over 1.8 billion people in the region [6] - EUDA is positioned to lead the transformation of regional healthcare from reactive treatment to proactive, longevity-focused care [6]

Core Viewpoint - Celularity Inc. has announced financing transactions that will provide up to $12 million to support its strategic priorities focused on longevity and human performance preservation [1] Financing Details - The financing includes a senior secured term loan of $7 million and secured convertible notes with commitments of up to $5 million, convertible at a price of $1.66 per share [3][4] - Initial proceeds of $10 million are expected, with an additional $2 million available under certain conditions [2] Strategic Focus - The financing is intended to enhance Celularity's mission by advancing its placental-derived technologies and aligning its organizational structure with its strategic priorities [3] - The investment reflects a commitment to support the company's long-term vision and operational alignment [4] Investor Insights - Philip A. Barach, the investor, emphasizes the importance of aligning strategy, operations, and capital structure to realize the company's scientific potential [4] - The investment is seen as a long-term commitment to provide financial support and constructive perspective as Celularity navigates necessary changes [4] Securities Information - The securities involved in the financing will be sold in a private placement exempt from registration requirements under the Securities Act of 1933 [4] - Celularity will file registration statements with the SEC for the resale of shares underlying the convertible notes and warrants [4]

Core Insights - Adia Labs has formed a strategic marketing partnership with BoldMD to enhance the expansion of Axia MD's chiropractor-hosted pop-up longevity clinics across the United States [1][2] Group 1: Partnership and Expansion - The collaboration with BoldMD builds on Adia Labs' existing partnership with Axia MD, which provides physician oversight in all 50 states, creating a compliant platform for scalable growth [2] - The pop-up clinics leverage a network of over 70,000 licensed chiropractors in the U.S., with the chiropractic profession expected to grow approximately 10% over the next decade, more than double the average growth rate for all occupations [3] Group 2: Marketing and Patient Acquisition - BoldMD will implement targeted patient acquisition campaigns, brand development, AI-powered CRM tools, and data-driven marketing strategies to enhance patient retention and optimize marketing efficiency [5] - The partnership aims to support rapid scaling as new clinic locations are launched nationwide, providing advanced regenerative therapies under full physician oversight [3][5] Group 3: Company Overview and Services - Adia Nutrition Inc. specializes in stem cell and regenerative products, with its lab division, Adia Labs LLC, expanding to include insurance-billable wound care products [7] - Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments, with a focus on innovative healthcare solutions [8]